跳到正文
原文
MedPage Today·· 2 天前AI 评分47

PVX108花生过敏肽疫苗II期试验:月注12个月显著提升儿童耐受阈值且安全性良好

Peanut Peptide Injections Promising for Allergy Immunotherapy

AI 导读

Emory大学Vickery团队在ACAAI年会报告,II期试验纳入71名4至11岁花生过敏患儿,随机分获5-nmol或50-nmol PVX108月注射或安慰剂共12个月。

正文

— A novel route to immunotherapy for peanut allergy passes phase II test

November 17, 2026 • 4 min read

A novel peptide-based immunotherapy for peanut allergy appeared safe and modestly efficacious for reducing children's symptoms over the first 12 months, a phase II trial showed.

For the primary efficacy endpoint, the higher of two monthly PVX108 shot dosages significantly boosted the maximum tolerated dose of peanut from baseline to month 12 by 2.4-fold, compared with a 1.2-fold change in the placebo group, reported Brian P. Vickery, MD, of Emory University and chief of the Division of Allergy/Immunology at Children's Healthcare of Atlanta, at the American College of Allergy, Asthma & Immunology annual meeting.

In terms of safety, there were no cases of anaphylaxis or other treatment-related allergic or severe adverse events with the shot. Only six of the 71 trial participants reported any adverse event (13% with the higher dose tested), largely local administration site reactions.

At an oral food challenge at 1 year, 39% of patients on the higher dose tolerated at least 300 mg of peanut protein compared with 17% in the placebo group (the equivalent of one peanut). "This is more than double, on average, what causes accidental reactions in the field when people are exposed accidentally while they're trying to avoid peanut. And it's been shown in previous work that ... is probably clinically meaningful for most patients with peanut allergy," Vickery said. But he acknowledged it "is probably less than what you'd expect in a study of oral immunotherapy, where the participants are swallowing about 300 mg of protein daily as part of their treatment."

While efficacy needs to be confirmed in a larger trial, "there's also a big safety difference and a difference in burden in terms of daily versus monthly therapy," he added, pointing to adverse events in most immunotherapy patients with other routes of administration and anaphylaxis in 10-15% of trial participants in some studies.

Immunotherapy shots offer an advantage of fewer office visits than the typically once-every-2-week schedule for oral immunotherapy up-dosing and also not requiring kids to consume peanut products daily, commented Jay Lieberman, MD, of the University of Tennessee Health Science Center in Memphis. With peanut protein, though, "you can't do it the same way we do allergy shots to cat or oak tree pollen, because it is too dangerous. It caused too many reactions," he said.

PVX108 comprises seven short peptides representing immunodominant T-cell epitopes of major peanut allergens rather than intact peanut proteins that interact with the immune system and can lead to reactions. "This is designed to get around that problem by formulating fragments of peanut proteins that are too small to interact with IgE [immunoglobulin E] and the allergic components of the immune system and instead interact directly with T cells, which are thought to be kind of the driving force behind the allergy," Vickery said.

"We have made some progress in being able to treat peanut allergy with oral immunotherapy and now FDA-approved omalizumab [Xolair] as the two most commonly used options," Vickery said in an interview monitored by media relations for drug developer Aravax. "But there are millions of patients out there with peanut allergy, and most of them are not being treated due to limitations in care and also limitations in access to these treatments and because of limitations in the treatments themselves."

"The scientific community believes that there is plenty of room for new forms of immunotherapy to be developed," he added, "because we don't think of peanut allergy as a one-size-fits-all condition where one treatment will solve the problem."

While the only FDA-approved peanut oral immunotherapy product recently left the market as clinicians rely on off-the-shelf commercial products, Lieberman agreed that PVX108 could find a place: "Bringing an [oral immunotherapy] FDA-approved thing to the market when people are already just using PB2 powder [commercially available peanut flour], that was the problem."

The trial included 71 peanut allergy patients ages 4 to 11 years at 14 trial sites in the U.S. and Australia in the primary efficacy and safety cohort. They were randomized to double-blind treatment with 5-nmol or 50-nmol PVX108 or placebo given monthly by intradermal administration over 12 months. At the end of that period, a double-blind placebo-controlled food challenge was done following the PRACTALL guidelines.

After 6 months off treatment, a follow-up food challenge was conducted at month 18. It showed evidence of maintenance or improvement in clinical effects compared with month 12, indicating disease-modifying potential, Vickery said, although this needs further confirmation.

The optimal length of treatment isn't clear yet, but immunotherapy shots for other allergens typically take 3 to 5 years of treatment, Vickery noted. "So it's likely that longer-term treatment might be necessary or even might be more optimal."

来源:MedPage Today · medpagetoday.com